Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
- PMID: 9041175
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
Abstract
Somatic mutations in DNA mismatch repair genes have been observed in sporadic tumors as well as cell lines and xenografts derived from such tumors implicating genetic defects of mismatch repair genes in the development of such tumors. However, the proportion of sporadic tumors in which mismatch repair genes have been inactivated has not been determined accurately. We have analyzed 66 sporadic colorectal tumors for the expression of hMLH1 by immunohistochemistry and identified 4 tumors that do not express hMLH1. These four colorectal tumors, a colon tumor cell line (SW48) and an endometrial tumor cell line (AN3CA), did not express hMLH1, despite the absence of mutations in its coding sequence. Cytosine methylation of the hMLH1 promoter region was found in these four colorectal tumors, whereas cytosine methylation of the hMLH1 promoter region was absent in adjacent normal tissue or in nine tumors that expressed hMLH1. In addition, cytosine methylation of the hMLH1 promoter region was observed in the SW48 and AN3CA cell lines that do not express hMLH1 but not in four tumor cell lines known to express hMLH1 mRNA. Our data indicate that DNA methylation is likely to be a common mode of mismatch repair gene inactivation in sporadic tumors.
Similar articles
-
Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.Cancer Res. 1999 May 1;59(9):2029-33. Cancer Res. 1999. PMID: 10232580
-
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.Cancer Res. 1998 Aug 1;58(15):3455-60. Cancer Res. 1998. PMID: 9699680
-
Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression.Oncogene. 2001 Oct 25;20(48):7120-7. doi: 10.1038/sj.onc.1204891. Oncogene. 2001. PMID: 11704838
-
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.Cancer Res. 2000 Nov 1;60(21):6039-44. Cancer Res. 2000. PMID: 11085525
-
DNA repair defects in colon cancer.Curr Opin Genet Dev. 2003 Feb;13(1):61-9. doi: 10.1016/s0959-437x(03)00004-2. Curr Opin Genet Dev. 2003. PMID: 12573437 Review.
Cited by
-
Aberrant protein expression and frequent allelic loss of MSH3 in colorectal cancer with low-level microsatellite instability.Int J Colorectal Dis. 2012 Jul;27(7):911-9. doi: 10.1007/s00384-011-1408-0. Epub 2012 Jan 10. Int J Colorectal Dis. 2012. PMID: 22249440
-
DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection.Oncol Lett. 2020 Sep;20(3):2435-2441. doi: 10.3892/ol.2020.11799. Epub 2020 Jul 1. Oncol Lett. 2020. PMID: 32782560 Free PMC article.
-
MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.J Pathol. 2013 Jan;229(1):99-110. doi: 10.1002/path.4087. J Pathol. 2013. PMID: 22899370 Free PMC article.
-
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.Cancer Treat Res. 2024;192:305-418. doi: 10.1007/978-3-031-61238-1_15. Cancer Treat Res. 2024. PMID: 39212927 Review.
-
Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma.BMC Cancer. 2005 Mar 1;5:23. doi: 10.1186/1471-2407-5-23. BMC Cancer. 2005. PMID: 15740628 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Other Literature Sources